Our study also reveals that the effect of co-inhibition of integrin/FAK pathway and BRD4 in NSCLC is not only equivalent to that of VS-6063 in combination with cisplatin or Osimertinib. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.